Human genetic variants of homologous recombination repair genes first found to be associated with Epstein-Barr virus antibody titers in healthy Cantonese

International Journal of Cancer

Volumn 129, Issue 6, 2011, Pages 1459-1466

  Shen, Guo Ping ^a   Pan, Qing Hua ^a   Hong, Ming Huang ^a   Qin, Hai De ^a   Xu, Ya Fei ^a   Chen, Li Zhen ^a   Feng, Qi Sheng ^a   Jorgensen, Timothy J ^b,c   Shugart, Yin Yao ^c   Zeng, Yi Xin ^a   Jia, Wei Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GEORGETOWN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

antiviral capsid antigen; Epstein Barr virus; homologous recombination repair; nasopharyngeal carcinoma; single nucleotide polymorphism

Indexed keywords

IMMUNOGLOBULIN A; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN ANTIBODY;

ANTIBODY TITER; ARTICLE; CANCER RISK; CHINA; CONTROLLED STUDY; DNA REPAIR; EPSTEIN BARR VIRUS; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE; HOMOLOGOUS RECOMBINATION; HUMAN; LEG3 GENE; MAJOR CLINICAL STUDY; MDC1 GENE; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RAD45L GENE; RFC1 GENE; RISK ASSESSMENT; RPA1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TP53BP1 GENE; VIRUS CARCINOGENESIS;

ADULT; ANTIBODIES, VIRAL; CAPSID; DNA REPAIR; FEMALE; GENOTYPE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINATION, GENETIC;

EID: 79960900653     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25759     Document Type: Article

References (46)

1. Cho WC,. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007; 6: 1.
2. Chang ET, Adami HO,. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1765-77. (Pubitemid 44664247)
3. Neel HB, III, Pearson GR, Taylor WF,. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Ann Otol Rhinol Laryngol 1984; 93: 477-82. (Pubitemid 15204757)
4. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR,. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 1982; 29: 139-41. (Pubitemid 12166994)
5. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS, Chan KH, Ng SP, Wei WI, Chua DT, Sham JS, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 2007; 96: 623-30.
6. Tsurumi T, Fujita M, Kudoh A,. Latent and lytic Epstein-Barr virus replication strategies. Rev Med Virol 2005; 15: 3-15. (Pubitemid 40070039)
7. Neuhierl B, Feederle R, Hammerschmidt W, Delecluse HJ,. Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection. Proc Natl Acad Sci USA 2002; 99: 15036-41. (Pubitemid 35334605)
8. Pearson GR,. Epstein-Barr virus and nasopharyngeal carcinoma. J Cell Biochem Suppl 1993; 17F: 150-4. (Pubitemid 23252934)
9. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, Yang CS,. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001; 345: 1877-82.
10. Hsu WL, Chen JY, Chien YC, Liu MY, You SL, Hsu MM, Yang CS, Chen CJ,. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Cancer Epidemiol Biomarkers Prev 2009; 18: 1218-26.
11. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, Liang JS, Qiu H,. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992; 69: 3-7.
12. Cheng WM, Chan KH, Chen HL, Luo RX, Ng SP, Luk W, Zheng BJ, Ji MF, Liang JS, Sham JS, Wang DK, Zong YS, et al. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer 2002; 97: 489-92. (Pubitemid 34027808)
13. Wong MM, Lye MS, Cheng HM, Sam CK,. Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma. Asian Pac J Allergy Immunol 2005; 23: 65-7. (Pubitemid 40790090)
14. Lu CC, Chen YC, Wang JT, Yang PW, Chen MR,. Xeroderma pigmentosum C is involved in Epstein Barr virus DNA replication. J Gen Virol 2007; 88: 3234-43.
15. Lu CC, Huang HT, Wang JT, Slupphaug G, Li TK, Wu MC, Chen YC, Lee CP, Chen MR,. Characterization of the uracil-DNA glycosylase activity of Epstein-Barr virus BKRF3 and its role in lytic viral DNA replication. J Virol 2007; 81: 1195-208. (Pubitemid 46167841)
16. Kudoh A, Iwahori S, Sato Y, Nakayama S, Isomura H, Murata T, Tsurumi T,. Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments. J Virol 2009; 83: 6641-51.
17. Bailey SG, Verrall E, Schelcher C, Rhie A, Doherty AJ, Sinclair AJ,. Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1. J Virol 2009; 83: 11116-22.
18. Kudoh A, Fujita M, Zhang L, Shirata N, Daikoku T, Sugaya Y, Isomura H, Nishiyama Y, Tsurumi T,. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem 2005; 280: 8156-63. (Pubitemid 40349716)
19. Chang SS, Lo YC, Chua HH, Chiu HY, Tsai SC, Chen JY, Lo KW, Tsai CH,. Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression. J Virol 2008; 82: 7745-51.
20. Zhang Q, Gutsch D, Kenney S,. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 1994; 14: 1929-38. (Pubitemid 24074588)
21. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S,. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 2002; 76: 12503-12. (Pubitemid 35386936)
22. Wilcock D, Lane DP,. Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature 1991; 349: 429-31. (Pubitemid 21926106)
23. Sinclair A, Yarranton S, Schelcher C,. DNA-damage response pathways triggered by viral replication. Expert Rev Mol Med 2006; 8: 1-11.
24. Fortunato EA, Spector DH,. p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. J Virol 1998; 72: 2033-9. (Pubitemid 28100757)
25. Yi Z, Yuxi L, Chunren L, Sanwen C, Jihneng W, Jisong Z, Huijong Z,. Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology 1980; 13: 162-8. (Pubitemid 10101692)
26. Feng BJ, Huang W, Shugart YY, Lee MK, Zhang F, Xia JC, Wang HY, Huang TB, Jian SW, Huang P, Feng QS, Huang LX, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet 2002; 31: 395-9. (Pubitemid 35154449)
27. Wood RD, Mitchell M, Sgouros J, Lindahl T,. Human DNA repair genes. Science 2001; 291: 1284-9. (Pubitemid 32173086)
28. Barrett JC, Fry B, Maller J, Daly MJ,. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5. (Pubitemid 40202029)
29. International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-96.
30. Steemers FJ, Chang W, Lee G, Barker DL, Shen R, Gunderson KL,. Whole-genome genotyping with the single-base extension assay. Nat Methods 2006; 3: 31-3. (Pubitemid 43135346)
31. Steemers FJ, Gunderson KL,. Illumina, Inc. Pharmacogenomics 2005; 6: 777-82. (Pubitemid 41479421)
32. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N,. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42. (Pubitemid 38443646)
33. Ho HC, Ng MH, Kwan HC,. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br J Cancer 1978; 37: 356-62. (Pubitemid 8368565)
34. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, Sun B, Hsu MM, Chen IH, Chen JY, Yang CS, Mittl BL, et al. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 2004; 111: 117-23. (Pubitemid 38859292)
35. Guo XC, Scott K, Liu Y, Dean M, David V, Nelson GW, Johnson RC, Dilks HH, Lautenberger J, Kessing B, Martenson J, Guan L, et al. Genetic factors leading to chronic Epstein-Barr virus infection and nasopharyngeal carcinoma in South East China: study design, methods and feasibility. Hum Genomics 2006; 2: 365-75. (Pubitemid 44110982)
36. Liu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, Wang WB, Chen JY,. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 2004; 23: 2531-9.
37. Huang DP, Ho JH, Chan WK, Lau WH, Lui M,. Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int J Cancer 1989; 43: 936-9. (Pubitemid 19138209)
38. Huang DP, Lo KW, Choi PH, Ng AY, Tsao SY, Yiu GK, Lee JC,. Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma. Cancer Genet Cytogenet 1991; 54: 91-9.
39. Shao JY, Huang XM, Yu XJ, Huang LX, Wu QL, Xia JC, Wang HY, Feng QS, Ren ZF, Ernberg I, Hu LF, Zeng YX,. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Anticancer Res 2001; 21: 3021-9. (Pubitemid 33051170)
40. Chang Y, Cheng SD, Tsai CH,. Chromosomal integration of Epstein-Barr virus genomes in nasopharyngeal carcinoma cells. Head Neck 2002; 24: 143-50. (Pubitemid 34111511)
41. Xie A, Hartlerode A, Stucki M, Odate S, Puget N, Kwok A, Nagaraju G, Yan C, Alt FW, Chen J, Jackson SP, Scully R,. Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. Mol Cell 2007; 28: 1045-57. (Pubitemid 350297033)
42. Eliezer Y, Argaman L, Rhie A, Doherty AJ, Goldberg M,. The direct interaction between 53BP1 and MDC1 is required for the recruitment of 53BP1 to sites of damage. J Biol Chem 2009; 284: 426-35.
43. Bekker-Jensen S, Lukas C, Melander F, Bartek J, Lukas J,. Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1. J Cell Biol 2005; 170: 201-11. (Pubitemid 41043803)
44. Minter-Dykhouse K, Ward I, Huen MS, Chen J, Lou Z,. Distinct versus overlapping functions of MDC1 and 53BP1 in DNA damage response and tumorigenesis. J Cell Biol 2008; 181: 727-35. (Pubitemid 351786979)
45. Landi S, Gemignani F, Canzian F, Gaborieau V, Barale R, Landi D, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, et al. DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res 2006; 66: 11062-9. (Pubitemid 44877007)
46. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, Zhang Q, Millikan RE, Lerner S, Dinney CP, Spitz MR,. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006; 78: 464-79. (Pubitemid 43291228)